Syndax Pharmaceuticals Announces Board and Officer Changes
Ticker: SNDX · Form: 8-K · Filed: Dec 20, 2024 · CIK: 1395937
| Field | Detail |
|---|---|
| Company | Syndax Pharmaceuticals Inc (SNDX) |
| Form Type | 8-K |
| Filed Date | Dec 20, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, board-of-directors, executive-appointments
Related Tickers: SNDX
TL;DR
Syndax just shuffled its board and execs. Big changes coming?
AI Summary
Syndax Pharmaceuticals, Inc. filed an 8-K on December 20, 2024, reporting changes in its board of directors and executive officers, including the election of new directors and potential changes in compensatory arrangements. The filing indicates a shift in the company's leadership structure.
Why It Matters
Changes in a company's board and executive team can signal strategic shifts or governance adjustments that may impact future operations and shareholder value.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty regarding future strategy and execution, potentially affecting the company's performance.
Key Numbers
- 001-37708 — Commission File Number (Identifies the company's SEC filing history.)
- 32-0162505 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Syndax Pharmaceuticals Inc (company) — Registrant
- December 20, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Waltham, Massachusetts (location) — Principal Executive Offices
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors and potential departure of certain officers, but specific names and details of the changes are not fully elaborated in the provided text.
Were there any new executive appointments?
The filing mentions 'Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers,' suggesting new appointments or changes to existing ones, though specific details are not in the excerpt.
What is the significance of the 'Departure of Directors or Certain Officers' item?
This item signifies that there have been changes in the company's leadership, with directors or key officers leaving their positions.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 20, 2024.
What is Syndax Pharmaceuticals' primary business?
Syndax Pharmaceuticals is in the 'PHARMACEUTICAL PREPARATIONS' industry, SIC code 2834.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 11.6 · Accepted 2024-12-20 17:00:08
Filing Documents
- sndx-20241220.htm (8-K) — 37KB
- 0000950170-24-139121.txt ( ) — 150KB
- sndx-20241220.xsd (EX-101.SCH) — 25KB
- sndx-20241220_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SYNDAX PHARMACEUTICALS, INC. Date: December 20, 2024 By: /s/ Michael A. Metzger Michael A. Metzger Chief Executive Officer